株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

アヘン (オピオイド) 中毒:パイプライン製品の分析

Opium (Opioid) Addiction - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 192749
出版日 ページ情報 英文 114 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.40円で換算しております。
Back to Top
アヘン (オピオイド) 中毒:パイプライン製品の分析 Opium (Opioid) Addiction - Pipeline Review, H2 2017
出版日: 2017年09月12日 ページ情報: 英文 114 Pages
概要

オピオイド中毒は、ある時期、オピオイドを定期的に使用していた後に発症します。アヘン (鎮静剤) の長期使用は、脳内の神経障害を引き起こします。痛みを軽減する神経細胞の変性によって、外部の供給源としてアヘン (鎮静剤) への身体的依存をもたらします。兆候や症状には、強い不安感、高揚感、精神病、抑鬱感、高血圧、食欲減退、身体的興奮、睡眠障害、骨の痛みなどがあります。素因として、年齢、薬物乱用の既往歴、薬物乱用の家族歴、タバコへの依存、精神的ストレスなどが挙げられます。

当レポートでは、アヘン (オピオイド) 中毒に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

アヘン (オピオイド) 中毒の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

アヘン (オピオイド) 中毒:企業で開発中の治療薬

アヘン (オピオイド) 中毒:大学/機関で研究中の治療薬

アヘン (オピオイド) 中毒:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

アヘン (オピオイド) 中毒:企業で開発中の製品

アヘン (オピオイド) 中毒:大学/機関で研究中の製品

アヘン (オピオイド) 中毒の治療薬開発に従事している企業

  • Alkermes Plc
  • Aoxing Pharmaceutical Company, Inc
  • BioDelivery Sciences International, Inc.
  • Camurus AB
  • Foresee Pharmaceuticals, LLC
  • Heron Therapeutics, Inc.
  • Indivior Plc
  • INSYS Therapeutics, Inc.
  • Omeros Corporation
  • Pfizer Inc.
  • Relmada Therapeutics, Inc.
  • Titan Pharmaceuticals, Inc.
  • Zynerba Pharmaceuticals, Inc.

アヘン (オピオイド) 中毒:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

アヘン (オピオイド) 中毒:最近のパイプライン動向

アヘン (オピオイド) 中毒:休止中のプロジェクト

アヘン (オピオイド) 中毒:開発が中止された製品

アヘン (オピオイド) 中毒:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9710IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Opium (Opioid) Addiction - Pipeline Review, H2 2017, provides an overview of the Opium (Opioid) Addiction (Central Nervous System) pipeline landscape.

Opioid Addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). This can lead to an inability for the body to stop pain because there are no endorphins to mask the pain initially. The degeneration of the nerve cells that reduce pain can lead to a physical dependence on opiates as an external supply source. Signs and symptoms include increased general anxiety, euphoria, psychosis, depression, high blood pressure, decreased appetite, physical agitation, difficulty sleeping and pain in the bones. The predisposing factors include age, a personal history of substance abuse, and family history of substance abuse, cigarette dependency and psychologic stress.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Opium (Opioid) Addiction - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Opium (Opioid) Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 6, 5, 7, 12 and 3 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

Opium (Opioid) Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Opium (Opioid) Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Opium (Opioid) Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Opium (Opioid) Addiction (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Opium (Opioid) Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Opium (Opioid) Addiction - Overview
    • Opium (Opioid) Addiction - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Opium (Opioid) Addiction - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Opium (Opioid) Addiction - Companies Involved in Therapeutics Development
    • Alkermes Plc
    • Aoxing Pharmaceutical Company Inc
    • BioCorRx Inc
    • BioDelivery Sciences International Inc
    • Camurus AB
    • Fab'entech SA
    • Foresee Pharmaceuticals LLC
    • Indivior Plc
    • Insys Therapeutics Inc
    • iX Biopharma Ltd
    • Nemus Bioscience Inc
    • Novartis AG
    • Omeros Corp
    • Opiant Pharmaceuticals Inc
    • Orexigen Therapeutics Inc
    • Orexo AB
    • Pfizer Inc
    • Relmada Therapeutics Inc
    • Teva Pharmaceutical Industries Ltd
    • Titan Pharmaceuticals Inc
    • Zynerba Pharmaceuticals Inc
  • Opium (Opioid) Addiction - Drug Profiles
    • (buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (buprenorphine hydrochloride + samidorphan l-malate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 18-MC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ANS-6637 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibody for Poisoning, Drug Overdose and Opioid Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AQU-010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • buprenorphine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • buprenorphine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • buprenorphine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • buprenorphine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • buprenorphine hydrochloride depot - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • buprenorphine hydrochloride SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • buprenorphine MR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cannabidiol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cannabidiol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Canquit-O - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FP-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mavoglurant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naltrexone hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naltrexone hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naltrexone hydrochloride SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NB-2111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NB-2222 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NT-814 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMS-405 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMS-527 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OREX-1019 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-4363467 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-5006739 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize D3 Receptor for Opioid Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TEV-90109 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Opioid Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Opium Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Opium (Opioid) Addiction - Dormant Projects
  • Opium (Opioid) Addiction - Discontinued Products
  • Opium (Opioid) Addiction - Product Development Milestones
    • Featured News & Press Releases
      • Sep 01, 2017: Indivior Responds To Court Rulings in ANDA Litigation and Announces Intention To Appeal
      • Aug 02, 2017: Zubsolv gains preferred position on CVS Caremark 2018 Formulary
      • Aug 02, 2017: Nemus Bioscience Announces Presentation of NB2111 Analgesic and Anti-Addiction Data at NIH-Sponsored Cannabinoid Conference
      • Jul 31, 2017: Indivior Announces FDA Acceptance with Priority Review Designation of RBP-6000 Buprenorphine Monthly Depot New Drug Application (NDA) for the Treatment of Opioid Use Disorder
      • Jul 25, 2017: BioCorRx Announces EnLite Clinics to Implement the BioCorRx Recovery Program in Three Clinics in Ohio
      • Jul 20, 2017: Braeburn and Camurus Announce Submission of NDA for Long-Acting Buprenorphine (CAM2038) for Opioid Use Disorder
      • Jul 10, 2017: Orexigen Announces Presentation of Data for OREX-1019, Candidate for the Treatment of Chronic Pain with Reduced Addiction Liability and the Treatment and Management of Opioid Drug Addiction
      • Jul 06, 2017: BioCorRx to Exhibit at ASAM Conference in Dallas, Texas
      • Jun 29, 2017: Fortune Article Highlights Titan Pharmaceuticals And Its ProNeura Technology
      • Jun 29, 2017: Indivior Provides Update on RBP-6000
      • Jun 22, 2017: Long-acting Buprenorphine Blocks Opioid Effects and Suppresses Withdrawal Symptoms
      • Jun 21, 2017: Indivior Presents Results from the Phase 3 Pivotal Study of RBP-6000 Buprenorphine Monthly Depot for the Treatment of Opioid Use Disorder
      • Jun 15, 2017: Braeburn Pharmaceuticals and Camurus Announce Presentations of Pivotal Clinical Study Data of Long-acting Buprenorphine
      • Jun 13, 2017: Braeburn and Knight Therapeutics Announce Filing of PROBUPHINE in Canada
      • Jun 06, 2017: TSRI Anti-Heroin Vaccine Found Effective in Non-Human Primates
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Opium (Opioid) Addiction, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Opium (Opioid) Addiction - Pipeline by Alkermes Plc, H2 2017
  • Opium (Opioid) Addiction - Pipeline by Aoxing Pharmaceutical Company Inc, H2 2017
  • Opium (Opioid) Addiction - Pipeline by BioCorRx Inc, H2 2017
  • Opium (Opioid) Addiction - Pipeline by BioDelivery Sciences International Inc, H2 2017
  • Opium (Opioid) Addiction - Pipeline by Camurus AB, H2 2017
  • Opium (Opioid) Addiction - Pipeline by Fab'entech SA, H2 2017
  • Opium (Opioid) Addiction - Pipeline by Foresee Pharmaceuticals LLC, H2 2017
  • Opium (Opioid) Addiction - Pipeline by Indivior Plc, H2 2017
  • Opium (Opioid) Addiction - Pipeline by Insys Therapeutics Inc, H2 2017
  • Opium (Opioid) Addiction - Pipeline by iX Biopharma Ltd, H2 2017
  • Opium (Opioid) Addiction - Pipeline by Nemus Bioscience Inc, H2 2017
  • Opium (Opioid) Addiction - Pipeline by Novartis AG, H2 2017
  • Opium (Opioid) Addiction - Pipeline by Omeros Corp, H2 2017
  • Opium (Opioid) Addiction - Pipeline by Opiant Pharmaceuticals Inc, H2 2017
  • Opium (Opioid) Addiction - Pipeline by Orexigen Therapeutics Inc, H2 2017
  • Opium (Opioid) Addiction - Pipeline by Orexo AB, H2 2017
  • Opium (Opioid) Addiction - Pipeline by Pfizer Inc, H2 2017
  • Opium (Opioid) Addiction - Pipeline by Relmada Therapeutics Inc, H2 2017
  • Opium (Opioid) Addiction - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017
  • Opium (Opioid) Addiction - Pipeline by Titan Pharmaceuticals Inc, H2 2017
  • Opium (Opioid) Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H2 2017
  • Opium (Opioid) Addiction - Dormant Projects, H2 2017
  • Opium (Opioid) Addiction - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Opium (Opioid) Addiction, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top